St Andrews Research Repository

St Andrews University Home
View Item 
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs

Thumbnail
View/Open
Sturkenboom_2021_CP_PopulationPharmacokinetics_CC.pdf (1.535Mb)
Date
06/03/2021
Author
Sturkenboom, Marieke G. G.
Märtson, Anne-Grete
Svensson, Elin M.
Sloan, Derek J.
Dooley, Kelly E.
van den Elsen, Simone H. J.
Denti, Paolo
Peloquin, Charles A.
Aarnoutse, Rob E.
Alffenaar, Jan-Willem C.
Keywords
QA75 Electronic computers. Computer science
RM Therapeutics. Pharmacology
Metadata
Show full item record
Abstract
Tuberculosis (TB) is still the number one cause of death due to an infectious disease. Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB treatment and help to prevent slow response to treatment, acquired drug resistance, and adverse drug effects. The aim of this review was to provide an update on the pharmacokinetics and pharmacodynamics of anti-TB drugs and to show how population pharmacokinetics and Bayesian dose adjustment can be used to optimize treatment. We cover aspects on preclinical, clinical, and population pharmacokinetics of different drugs used for drug-susceptible TB and multidrug-resistant TB. Moreover, we include available data to support therapeutic drug monitoring of these drugs and known pharmacokinetic and pharmacodynamic targets that can be used for optimization of therapy. We have identified a wide range of population pharmacokinetic models for first- and second-line drugs used for TB, which included models built on NONMEM, Pmetrics, ADAPT, MWPharm, Monolix, Phoenix, and NPEM2 software. The first population models were built for isoniazid and rifampicin; however, in recent years, more data have emerged for both new anti-TB drugs, but also for defining targets of older anti-TB drugs. Since the introduction of therapeutic drug monitoring for TB over 3 decades ago, further development of therapeutic drug monitoring in TB next steps will again depend on academic and clinical initiatives. We recommend close collaboration between researchers and the World Health Organization to provide important guideline updates regarding therapeutic drug monitoring and pharmacokinetics/pharmacodynamics.
Citation
Sturkenboom , M G G , Märtson , A-G , Svensson , E M , Sloan , D J , Dooley , K E , van den Elsen , S H J , Denti , P , Peloquin , C A , Aarnoutse , R E & Alffenaar , J-W C 2021 , ' Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs ' , Clinical Pharmacokinetics . https://doi.org/10.1007/s40262-021-00997-0
Publication
Clinical Pharmacokinetics
Status
Peer reviewed
DOI
https://doi.org/10.1007/s40262-021-00997-0
ISSN
1179-1926
Type
Journal item
Rights
Copyright © The Author(s) 2021. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Description
Funding: Anne-Grete Märtson was funded by Marie Skłodowska-Curie Actions [Grant agreement no. 713660—PRONKJEWAIL—H2020-MSCA-COFUND-2015].
Collections
  • University of St Andrews Research
URI
http://hdl.handle.net/10023/21654

Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

Advanced Search

Browse

All of RepositoryCommunities & CollectionsBy Issue DateNamesTitlesSubjectsClassificationTypeFunderThis CollectionBy Issue DateNamesTitlesSubjectsClassificationTypeFunder

My Account

Login

Open Access

To find out how you can benefit from open access to research, see our library web pages and Open Access blog. For open access help contact: openaccess@st-andrews.ac.uk.

Accessibility

Read our Accessibility statement.

How to submit research papers

The full text of research papers can be submitted to the repository via Pure, the University's research information system. For help see our guide: How to deposit in Pure.

Electronic thesis deposit

Help with deposit.

Repository help

For repository help contact: Digital-Repository@st-andrews.ac.uk.

Give Feedback

Cookie policy

This site may use cookies. Please see Terms and Conditions.

Usage statistics

COUNTER-compliant statistics on downloads from the repository are available from the IRUS-UK Service. Contact us for information.

© University of St Andrews Library

University of St Andrews is a charity registered in Scotland, No SC013532.

  • Facebook
  • Twitter